EMR three-lens brief
Evidence-based stock research on EMR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Analyst mean target $164.17 — 16% above current (27 analysts). · Debt-to-equity of 69.3 — balance-sheet-heavy.
- Analyst mean target $164.17 — 16% above current (27 analysts).
- Debt-to-equity of 69.3 — balance-sheet-heavy.
EMR closed at $141.35 (-0.77%) as of 2026-04-25. Market cap: $79.44B. P/E (trailing) 34.6. Positives: analyst mean target $164.17 — 16% above current (27 analysts).. Concerns: debt-to-equity of 69.3 — balance-sheet-heavy.. Last quarter: Revenue $4.35B, net income $605.00M, free cash flow $2.88B.
Why three lenses on EMR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine EMRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/EMR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath EMR brief"></iframe>